Sinovation Secures Nearly RMB 300 Million in Series D Financing with CEC Capital as Exclusive Financial Advisor

Sinovation (Beijing) Medical Technology Co., Ltd. (referred to as Sinovation), a leading Chinese intelligent platform for minimally invasive neurosurgery, recently announced the closing of nearly RMB 300 million in Series D financing. The round was led by China-U.S. Green Fund, with participation from DNV Capital, Banyan Pacific Capital, and continued investment from existing shareholder Co-win Ventures.

CEC Capital served as the exclusive financial advisor to Sinovation in this transaction.

With this latest funding, Sinovation has successfully completed the acquisition of Beijing Huake Hengsheng Medical Technology Co., Ltd., expanding its product line into the field of intracranial electrodes and further enriching its portfolio of precise neurosurgical products. Additionally, the company will accelerate the expansion of its pioneering Magnetic Resonance Imaging-guided intracranial laser ablation product (LITT) in its applications, bringing revolutionary and innovative treatment options to benefit a wide range of epilepsy and intracranial tumor patients in China, offering safe, precise, and minimally invasive therapeutic choices.